logo-loader
viewAvacta Group PLC

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst Ed Stacey

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space.

The group's reported interim results to January 2019 today, revealing revenues of £1.0mln and illustrating good progress on its key development programmes.

Quick facts: Avacta Group PLC

Price: 20.25 GBX

AIM:AVCT
Market: AIM
Market Cap: £35.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

Proactive Research analyst Ed Stacey says Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in 2020, with an opportunity now identified for a targeted chemotherapy programme to enter clinical trials during the first half. Stacey says alongside the recent...

3 weeks, 6 days ago

RNS

Holding(s) in Company

1 week, 1 day ago

Holding(s) in Company

1 week, 4 days ago

Holding(s) in Company

1 week, 4 days ago

Holding(s) in Company

1 week, 5 days ago

Holding(s) in Company

1 week, 5 days ago

Holding(s) in Company

1 week, 6 days ago

Result of General Meeting

2 weeks, 1 day ago

2 min read